CSTL vs NTRA

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 56. 7% revenue growth year-over-year, versus 3. 7% for Castle Biosciences, Inc. (CSTL). Analysts rate Castle Biosciences, Inc. (CSTL) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +123. 3%, compared to -56. 0% for Castle Biosciences, Inc. (CSTL). Over 10 years, the gap is even starker: NTRA returned +21. 5% versus CSTL's +15. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Castle Biosciences, Inc.

(CSTL) is the lower-risk stock at 0. 88β versus Natera, Inc. 's 1. 26β — meaning NTRA is approximately 42% more volatile than CSTL relative to the S&P 500. On balance sheet safety, Castle Biosciences, Inc. (CSTL) carries a lower debt/equity ratio of 8% versus 16% for Natera, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 56. 7% versus 3. 7% for Castle Biosciences, Inc. (CSTL). On earnings-per-share growth, the picture is similar: Natera, Inc. grew EPS 59. 5% year-over-year, compared to -233. 9% for Castle Biosciences, Inc.. Over a 3-year CAGR, NTRA leads at 39. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Castle Biosciences, Inc.

(CSTL) is the more profitable company, earning -7. 0% net margin versus -11. 2% for Natera, Inc. — meaning it keeps -7. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CSTL leads at -12. 4% versus -13. 1% for NTRA. At the gross margin level — before operating expenses — CSTL leads at 68. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Castle Biosciences, Inc.

(CSTL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 88)). Both have compounded well over 10 years (CSTL: +15. 7%, NTRA: +21. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CSTL is a small-cap quality compounder stock; NTRA is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.